PTJ
DMRA

Paul Tudor Jones’s Damora Therapeutics DMRA Stock Holding History

Paul Tudor Jones’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,164
Closed -$274K – 2583
2021
Q2 		$274K Sell
2,164
-154
-7% -$21K 0.01% 1381
2021
Q1 		$352K Sell
2,318
-259
-10% -$70.4K 0.01% 1251
2020
Q4 		$806K Buy
+2,577
New +$958K 0.02% 765

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's DMRA Position: Q3 2021 in Review

Paul Tudor Jones sold out of Damora Therapeutics (DMRA) in Q3 2021, closing a stake of 2,164 shares — an estimated $274K sold.

Paul Tudor Jones first reported a position in DMRA in Q4 2020 and held it in 3 quarters. The position peaked at $806K in Q4 2020. 25 funds tracked by Wall St. Rank hold DMRA as of Q3 2021.

  • Paul Tudor Jones reported no remaining Damora Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 2,164 Damora Therapeutics shares in Q3 2021, an estimated $274K.
  • Paul Tudor Jones first reported a position in Damora Therapeutics in Q4 2020 and held it in 3 quarters.
  • Paul Tudor Jones's Damora Therapeutics position peaked at $806K in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.